SARS-CoV-2 Mpro inhibitors: identification of anti-SARS-CoV-2 Mpro compounds from FDA approved drugs. 2022

Shiv Bharadwaj, and Esam Ibraheem Azhar, and Mohammad Amjad Kamal, and Leena Hussein Bajrai, and Amit Dubey, and Kanupriya Jha, and Umesh Yadava, and Sang Gu Kang, and Vivek Dhar Dwivedi
Department of Biotechnology, Institute of Biotechnology, College of Life and Applied Sciences, Yeungnam University, Gyeongsan, Republic of Korea.

Recent outbreak of COVID-19 pandemic caused by severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) has raised serious global concern for public health. The viral main 3-chymotrypsin-like cysteine protease (Mpro), known to control coronavirus replication and essential for viral life cycle, has been established as an essential drug discovery target for SARS-CoV-2. Herein, we employed computationally screening of Druglib database containing FDA approved drugs against active pocket of SARS-CoV-2 Mpro using MTiopen screen web server, yields a total of 1051 FDA approved drugs with docking energy >-7 kcal/mol. The top 10 screened potential compounds against SARS-CoV-2 Mpro were then studied by re-docking, binding affinity, intermolecular interaction, and complex stability via 100 ns all atoms molecular dynamics (MD) simulation followed by post-simulation analysis, including end point binding free energy, essential dynamics, and residual correlation analysis against native crystal structure ligand N3 inhibitor. Based on comparative molecular simulation and interaction profiling of the screened drugs with SARS-CoV-2 Mpro revealed R428 (-10.5 kcal/mol), Teniposide (-9.8 kcal/mol), VS-5584 (-9.4 kcal/mol), and Setileuton (-8.5 kcal/mol) with stronger stability and affinity than other drugs and N3 inhibitor; and hence, these drugs are advocated for further validation using in vitro enzyme inhibition and in vivo studies against SARS-CoV-2 infection.Communicated by Ramaswamy H. Sarma.

UI MeSH Term Description Entries
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000093485 COVID-19 Drug Treatment The use of DRUGS to treat COVID19 or its symptoms. COVID-19 Drug Therapy,COVID19 Drug Therapy,COVID19 Drug Treatment,Coronavirus Disease 2019 Drug Treatment,Coronavirus Disease-19 Drug Treatment,COVID 19 Drug Therapy,COVID 19 Drug Treatment,COVID-19 Drug Therapies,COVID19 Drug Therapies,COVID19 Drug Treatments,Coronavirus Disease 19 Drug Treatment,Drug Therapy, COVID-19,Drug Therapy, COVID19,Therapy, COVID-19 Drug,Therapy, COVID19 Drug,Treatment, COVID-19 Drug
D056004 Molecular Dynamics Simulation A computer simulation developed to study the motion of molecules over a period of time. Molecular Dynamics Simulations,Molecular Dynamics,Dynamic, Molecular,Dynamics Simulation, Molecular,Dynamics Simulations, Molecular,Dynamics, Molecular,Molecular Dynamic,Simulation, Molecular Dynamics,Simulations, Molecular Dynamics
D058873 Pandemics Epidemics of infectious disease that have spread to many countries, often more than one continent, and usually affecting a large number of people. Pandemic
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Shiv Bharadwaj, and Esam Ibraheem Azhar, and Mohammad Amjad Kamal, and Leena Hussein Bajrai, and Amit Dubey, and Kanupriya Jha, and Umesh Yadava, and Sang Gu Kang, and Vivek Dhar Dwivedi
February 2021, Physical biology,
Shiv Bharadwaj, and Esam Ibraheem Azhar, and Mohammad Amjad Kamal, and Leena Hussein Bajrai, and Amit Dubey, and Kanupriya Jha, and Umesh Yadava, and Sang Gu Kang, and Vivek Dhar Dwivedi
December 2022, Biomedicines,
Shiv Bharadwaj, and Esam Ibraheem Azhar, and Mohammad Amjad Kamal, and Leena Hussein Bajrai, and Amit Dubey, and Kanupriya Jha, and Umesh Yadava, and Sang Gu Kang, and Vivek Dhar Dwivedi
June 2020, Antimicrobial agents and chemotherapy,
Shiv Bharadwaj, and Esam Ibraheem Azhar, and Mohammad Amjad Kamal, and Leena Hussein Bajrai, and Amit Dubey, and Kanupriya Jha, and Umesh Yadava, and Sang Gu Kang, and Vivek Dhar Dwivedi
June 2021, RSC advances,
Shiv Bharadwaj, and Esam Ibraheem Azhar, and Mohammad Amjad Kamal, and Leena Hussein Bajrai, and Amit Dubey, and Kanupriya Jha, and Umesh Yadava, and Sang Gu Kang, and Vivek Dhar Dwivedi
December 2020, Journal of microbiology and biotechnology,
Shiv Bharadwaj, and Esam Ibraheem Azhar, and Mohammad Amjad Kamal, and Leena Hussein Bajrai, and Amit Dubey, and Kanupriya Jha, and Umesh Yadava, and Sang Gu Kang, and Vivek Dhar Dwivedi
November 2020, RSC advances,
Shiv Bharadwaj, and Esam Ibraheem Azhar, and Mohammad Amjad Kamal, and Leena Hussein Bajrai, and Amit Dubey, and Kanupriya Jha, and Umesh Yadava, and Sang Gu Kang, and Vivek Dhar Dwivedi
August 2021, Acta pharmacologica Sinica,
Shiv Bharadwaj, and Esam Ibraheem Azhar, and Mohammad Amjad Kamal, and Leena Hussein Bajrai, and Amit Dubey, and Kanupriya Jha, and Umesh Yadava, and Sang Gu Kang, and Vivek Dhar Dwivedi
March 2023, Journal of biomolecular structure & dynamics,
Shiv Bharadwaj, and Esam Ibraheem Azhar, and Mohammad Amjad Kamal, and Leena Hussein Bajrai, and Amit Dubey, and Kanupriya Jha, and Umesh Yadava, and Sang Gu Kang, and Vivek Dhar Dwivedi
January 2023, Journal of chemical research,
Shiv Bharadwaj, and Esam Ibraheem Azhar, and Mohammad Amjad Kamal, and Leena Hussein Bajrai, and Amit Dubey, and Kanupriya Jha, and Umesh Yadava, and Sang Gu Kang, and Vivek Dhar Dwivedi
November 2020, RSC advances,
Copied contents to your clipboard!